Subscribe
  
IPQ Inside the global regulatory dialogue

Strengthening Biotherapeutic Regulation Worldwide Will Remain a High Priority for WHO in 2017

Jan 30th, 2017

Please Log in to print the full article

Strengthening the capacity of governments around the world to regulate biotherapeutics and biosimilars in the effort to increase patient access to high quality products will remain a key priority for the World Health Organization (WHO) in 2017.

Underpinning the increased focus WHO is placing on biotherapeutic product regulation and access are resolutions passed by WHO’s oversight body, the World Health Assembly, in 2014, directing WHO to assist member states in strengthening their regulatory frameworks [IPQ Dec. 17, 2015].

In the wake of the resolutions, WHO’s Expert Committee on Biological Standardization (ECBS) has been active in its international standards development and implementation program for new and similar biotherapeutics (BTPs/SBPs) as well as vaccines, and has a substantial project workload set for 2017.

[The story continues for subscribers on p. 2.  Nonsubscribers can get information on IPQ subscriptions and licensing or individual story purchasing by contacting Wayne Rhodes (rhodes@IPQpubs.com).]

Pages: 1 2
  • Share/Bookmark

©2017 IPQ Publications